Covidien’s Webster Groves, Mo., Pilot Plant, the research and development center for oral solid dose research, focuses on formulation research for generic pharmaceuticals, primarily involving Covidien’s active pharmaceutical ingredients. This pilot plant adds significant capacity to the company’s product development capability by permitting Covidien to work on four products, simultaneously.
The design of the new $21.5-million pilot plant in Webster Groves, Mo., empowers Covidien’s scientists to develop up to five new drug products simultaneously. The equipment and the processing suites were built to handle potent compounds, to prevent cross-contamination and provide maximum safety for the employees and surrounding community.